U.S. markets close in 5 hours 59 minutes
  • S&P 500

    3,876.69
    +65.54 (+1.72%)
     
  • Dow 30

    31,500.81
    +568.44 (+1.84%)
     
  • Nasdaq

    13,412.07
    +219.73 (+1.67%)
     
  • Russell 2000

    2,255.20
    +54.15 (+2.46%)
     
  • Crude Oil

    61.71
    +0.21 (+0.34%)
     
  • Gold

    1,732.10
    +3.30 (+0.19%)
     
  • Silver

    26.91
    +0.47 (+1.76%)
     
  • EUR/USD

    1.2044
    -0.0044 (-0.36%)
     
  • 10-Yr Bond

    1.4220
    -0.0380 (-2.60%)
     
  • GBP/USD

    1.3920
    -0.0003 (-0.02%)
     
  • USD/JPY

    106.5930
    +0.0910 (+0.09%)
     
  • BTC-USD

    48,167.66
    +3,557.85 (+7.98%)
     
  • CMC Crypto 200

    966.53
    +38.30 (+4.13%)
     
  • FTSE 100

    6,568.39
    +84.96 (+1.31%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

COPENHAGEN, Denmark, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the upcoming 38th Annual J.P. Morgan Healthcare Conference. Company executives will provide a business overview and update on the company’s pipeline programs.

Details

Event

38th Annual J.P. Morgan Healthcare Conference

Location

San Francisco

Date

Monday, January 13, 2020

Time

Presentation: 8:00 a.m. Pacific Time (PT)
Question & Answer Session: 8:30 a.m. PT

Live webcasts of both the presentation and Q&A session will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create new and potentially best-in-class therapies and (iii) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2018, which we filed with the SEC on April 3, 2019. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. ©January 2020 Ascendis Pharma A/S.

Internal contact:

Media contact:

Investor contact:

Scott T. Smith

Ami Knoefler

Patti Bank

Chief Financial Officer

Head of Global Communications

Westwicke Partners

(650) 352-8389

(650) 739-9952

(415) 513-1284

ir@ascendispharma.com

ack@ascendispharma.com

patti.bank@westwicke.com